Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Diagnostic and prognostic value of biochemical markers in malignant bone disease: A prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease
Autore:
Engler, H; Koeberle, D; Thuerlimann, B; Senn, HJ; Riesen, WF;
Indirizzi:
Inst Clin Chem & Hematol, CH-9001 St Gallen, Switzerland Inst Clin Chem & Hematol St Gallen Switzerland CH-9001 llen, Switzerland Kantonsspital,witzerlandrnal Med C, Div Hematol Oncol, CH-9007 St Gallen, S Kantonsspital St Gallen Switzerland CH-9007 Oncol, CH-9007 St Gallen, S
Titolo Testata:
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
fascicolo: 11, volume: 36, anno: 1998,
pagine: 879 - 885
SICI:
1434-6621(199811)36:11<879:DAPVOB>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
PYRIDINIUM CROSS-LINKS; I COLLAGEN; TERMINAL TELOPEPTIDE; PROSTATE-CANCER; DEGRADATION; RESORPTION; PROTEIN; PYRIDINOLINE; IMMUNOASSAY; METASTASES;
Keywords:
bisphosphonate therapy; bone markers; osteolytic bone disease; prognostic markers; diagnostic markers;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Riesen, WF Inst Clin Chem & Hematol, Frohbergstr 3, CH-9001 St Gallen, Switzerland Inst Clin Chem & Hematol Frohbergstr 3 St Gallen Switzerland CH-9001
Citazione:
H. Engler et al., "Diagnostic and prognostic value of biochemical markers in malignant bone disease: A prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease", CLIN CH L M, 36(11), 1998, pp. 879-885

Abstract

Seventy cancer patients with malignant osteolytic bone disease received pamidronate every three weeks for a maximum of six cycles. Bone resorption parameters, urinary calcium excretion, and pain parameters were assessed at baseline and throughout the study. At baseline, 80-95 % of patients showed elevated urinary pyridinoline, deoxypyridinoline, Osteomark(R) NTx and serumICTP(R) levels, whereas only 35 % of patients had elevated urinary CrossLaps(R) excretion rates. During bisphosphonate therapy, significant decreasesin Osteomark(R) NTx, CrossLaps(R) and calcium excretion were observed, which were not related to the clinical outcome. The baseline levels of bone resorption markers were used to predict the probability of non-progressive bone disease or reduction in pain intensity during bisphosphonate therapy. Significant predictors of non-progressive bone disease were urinary pyridinoline and serum ICTP levels; significant predictors of reduction in pain intensity were urinary free deoxypyridinoline and serum ICTP levels. Our data indicate that serum ICTP levels predict significantly the response to bisphosphonate therapy in patients with advanced malignant osteolytic bone disease. CrossLaps did not predict the clinical outcome, but decreasedsignificantly during bisphosphonate therapy. Our data demonstrate that thedifferent bone resorption markers are reflecting different aspects of bonemetabolism, and therefore differ in their diagnostic and prognostic properties.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/07/20 alle ore 20:52:50